<DOC>
	<DOC>NCT01199536</DOC>
	<brief_summary>The Study purpose is to evaluate Helicobacter pylori susceptibility to Clarithromycin and to estimate eradication and healing rates of duodenal ulcer routine eradication therapy at the end of treatment and 52 weeks from the therapy start</brief_summary>
	<brief_title>Helicobacter Pylori Eradication Treatment in Patients With Duodenal Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<criteria>Active duodenal ulcer with duodenal ulcer exacerbation confirmed by endoscopic signs of duodenal ulcer disease (acute ulcer or scar deformity of the duodenal bulb) and anamnesis data. Helicobacter pylori positive diagnosis at entry by 13CUrea Breath Test (UBT) Prescription of the standard 7day eradication therapy including esomeprazole 20 mg bd, amoxicillin 1000 mg bd, clarithromycin 500 mg bd Written informed consent provided prior the start of participation in the study. Subjects who are unwilling or unable to provide informed consent Current complication of duodenal ulcer disease, e.g. perforation, bleeding or pyloric stenosis History of esophageal/gastric/duodenal surgery except of the patients underwent perforated ulcer closure or endoscopic hemostasis more than 6 months ago Contraindications to Esomeprazole, Amoxicillin or Clarythromycin including known or suspected hypersensitivity or allergy Treatment with Amoxicillin, Clarythromycin or Bismuth containing drugs one month prior to inclusion Two or more previous attempts to eradicate H. Pylori</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Helicobacter-positive duodenal ulcer</keyword>
</DOC>